Abstract:Background Spinal cord injury (SCI) is a severe neurological disorder with many disabling consequences, including persistent neuropathic pain, which develops in about 40 % of SCI patients and is induced and sustained by excessive and uncontrolled spinal neuroinflammation. Here, we have evaluated the effects of lipoxin A4 (LXA4), a member of a unique class of endogenous lipid mediators with both anti-inflammatory and analgesic properties, on spinal neuroinflammation and chronic pain in an experimental model of SCI. Methods Spinal hemisection at T10 was carried out in adult male CD1 mice and Wistar rats. To test if LXA4 can reduce neuroinflammation and neuropathic pain, each animal received two intrathecal injections of LXA4 (300 pmol) or vehicle at 4 and 24 h after SCI. Sensitivity to mechanical stimulation of the hind paws was evaluated using von Frey monofilaments, and neuroinflammation was tested by measuring the mRNA and/or protein expression levels of glial markers and cytokines in the spinal cord samples after SCI. Also, microglia cultures prepared from murine cortical tissue were used to assess the direct effects of LXA4 on microglial activation and release of pro-inflammatory TNF-α. Results LXA4 treatment caused significant reductions in the intensity of mechanical pain hypersensitivity and spinal expression levels of microglial markers and pro-inflammatory cytokines induced by SCI, when compared to rodents receiving control vehicle injections. Notably, the increased expressions of the microglial marker IBA-1 and of the pro-inflammatory cytokine TNF-α were the most affected by the LXA4 treatment. Furthermore, cortical microglial cultures expressed ALX/FPR2 receptors for LXA4 and displayed potentially anti-inflammatory responses upon challenge with LXA4. Conclusions Collectively, our results suggest that LXA4 can effectively modulate microglial activation and TNF-α release through ALX/FPR2 receptors, ultimately reducing neuropathic pain in rodents after spinal cord hemisection. The dual anti-inflammatory and analgesic properties of LXA4, allied to its endogenous nature and safety profile, may render this lipid mediator as new therapeutic approach for treating various neuroinflammatory disorders and chronic pain with only limited side effects.

Lipoxins in the Nervous System: Brighter Prospects for Neuroprotection

Protective Effect of Lipoxins on Neurological Disorders

Lipoxin A4 Analogue Protects Brain and Reduces Inflammation in a Rat Model of Focal Cerebral Ischemia Reperfusion.

Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection

Lipoxin A4 Ameliorates Cerebral Ischaemia/reperfusion Injury Through Upregulation of Nuclear Factor Erythroid 2-Related Factor 2.

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Lipoxin A 4 Inhibits 5-Lipoxygenase Translocation and Leukotrienes Biosynthesis to Exert a Neuroprotective Effect in Cerebral Ischemia/Reperfusion Injury

LXR agonism for CNS diseases: promises and challenges

Lipoxins and Liver Diseases

LXA4 protects against hypoxic-ischemic damage in neonatal rats by reducing the inflammatory response via the IκB/NF-κB pathway

Lipoxins A4 and B4 inhibit glial cell activation via CXCR3 signaling in acute retinal neuroinflammation

JLX001 Modulated the Inflammatory Reaction and Oxidative Stress in Pmcao Rats Via Inhibiting the TLR2/4-NF-κB Signaling Pathway

Protective role of lipoxins in digestive diseases

JLX001 Ameliorates Cerebral Ischemia Injury by Modulating Microglial Polarization and Compromising NLRP3 Inflammasome Activation Via the NF-κB Signaling Pathway

Recent Research Progress on the Mechanism of Lipoxins Promoting Phagocytosis

Protective Effects of Lipoxin A and B Signaling on the Inner Retina in a Mouse Model of Experimental Glaucoma

Neuroprotective Effect of Lipoxin A 4 Methyl Ester in a Rat Model of Permanent Focal Cerebral Ischemia

JLX001 Ameliorates Ischemia/Reperfusion Injury by Reducing Neuronal Apoptosis Via Down-Regulating JNK Signaling Pathway.

Discovery of neuroprotective Agents: Potent, brain Penetrating, lipoic acid derivatives for the potential treatment of ischemic stroke by regulating oxidative stress and inflammation - a Preliminary study

Lipoxygenase Metabolism: Critical Pathways in Microglia-mediated Neuroinflammation and Neurodevelopmental Disorders

Brain response to injury and neurodegeneration: endogenous neuroprotective signaling